NextBioMedical Co

NextBioMedical Co Long-term Debt

The Long-Term Debt of NextBioMedical Co (389650.KQ) as of Nov 19, 2026 is 950.66 M KRW. In the previous year, Long-Term Debt was 784.08 M KRW — a change of 21.25% (higher).

Long-term Debt

950.66 MKRW

YoY

21.25%

Last updated:

Long-Term Debt of NextBioMedical Co is 2025 950.66 M KRW. Long-Term Debt of NextBioMedical Co was 2024 784.08 M KRW. It decreases by 21.25% higher compared to the previous year.

The NextBioMedical Co Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2022
581.63 M KRW
Jan 1, 2023
980.44 M KRW
Jan 1, 2024
784.08 M KRW
Jan 1, 2025
950.66 M KRW
The NextBioMedical Co Long-term Debt history
YEARLong-term DebtYoY
950.66 MKRW+21.25%
784.08 MKRW-20.03%
980.44 MKRW+68.57%
581.63 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextBioMedical Co Stock analysis

What does NextBioMedical Co do? NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings. The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care. NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry. NextBioMedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextBioMedical Co stock

Long-Term Debt of NextBioMedical Co is 950.66 M KRW in 2025.

Long-Term Debt of NextBioMedical Co changed from 784.08 M KRW to 950.66 M KRW, representing a 21.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's NextBioMedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — NextBioMedical Co

All Key Metrics — NextBioMedical Co